<DOC>
	<DOCNO>NCT01174563</DOCNO>
	<brief_summary>This open-label , single arm study assess correlation Tarceva ( erlotinib ) -induced rash efficacy patient inoperable , locally advanced , recurrent metastatic non-small cell lung cancer ( NSCLC ) receive first-line therapy advance disease . Patients receive Tarceva dose 150 mg daily orally , dose adjustment accord protocol depend toxicity . Anticipated time study treatment disease progression occur .</brief_summary>
	<brief_title>A Study Correlation Between Tarceva ( Erlotinib ) - Induced Rash Efficacy EGFR Mutated Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Inoperable , locally advanced , recurrent metastatic ( Stage IIIB IV ) nonsmall cell lung cancer ( NSCLC ) Presence epidermal growth factor receptor ( EGFR ) mutation Previously untreated systemic antineoplastic therapy advance disease Last dose prior systemic antineoplastic therapy earlystage disease &gt; /= 4 week study start , patient recover acute toxicity previous therapy Pregnant breast feed woman Known allergy adverse reaction study drug relate compound Prior systemic antineoplastic therapy HER1/EGFR inhibitor ( small molecule monoclonal antibody therapy ) Newly diagnose yet definitively treat ( i.e . stable disease &gt; /= 2 month ) CNS metastases spinal cord compression Any significant ophthalmological abnormality , especially likely increase risk corneal epithelial lesion ( use contact lens recommend study ) Active cancer NSCLC , except basal cell squamous cell carcinoma skin excise cured</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>